Furthermore, EPHRIN B2 could be applied to the antigen-recognition domain of the CAR construct to harness EPHB4-expressing tumor cells to genetically modify CAR-T cells that lack the proliferative tendency of tumor cells via ligand-antigen interaction. Here, EPHB4 is linked to neoplasm.